(Adnkronos) - Coco (Novartis), siamo molto orgogliosi di questo risultato che potrà finalmente offrire ai pazienti con questo tipo di tumore resistente alla castrazione una nuova opportunità terapeutica, del tutto italiana, in grado di prolungare l’aspettativa di vita mantenendo e preservando una buona qualità di vita. Ci aspettiamo che questa terapia possa essere disponibile intorno al mese di marzo.
Category
🗞
NewsTranscript
00:00Novartis has been committed for more than 20 years to the development of innovative drugs and new technological platforms
00:14that can somehow respond to all unsatisfied clinical needs with a high clinical load.
00:24Today we are very proud of this result that we have obtained thanks to an incessant collaboration with regulatory authorities
00:35that will finally be able to offer patients affected by prostatic carcinoma resistant to castration
00:44a new therapeutic opportunity to prolong life expectancy by maintaining and preserving a good quality of life as much as possible.
00:55One thing that makes us particularly proud is the fact that this new therapy with radioligands has a totally Italian brand.
01:06It was born from an idea of Professor Buono who, already at the beginning of the 2000s, through a small start-up,
01:15started this path in the field of therapy and the platform with radioligands.
01:22Today they are produced in Italy in the Ivrea production site, which is one of the few production sites in the world for this new technological platform
01:34and which is part of the Novartis group.
01:40Today we have reached an agreement with regulatory authorities and we expect this therapy to be available to all patients
01:54who have the necessary characteristics around March.
01:59We obviously hope that the path of access at the regional level can be rapid
02:07so that the therapeutic option becomes a reality for all patients effectively.